Navigation Links
3SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results
Date:2/11/2010

therapy licensed through a strategic partnership with AMAG Pharmaceuticals. -- A collaboration and license agreement was signed with Panacor Bioscience to develop and commercialize Nephoxil(R), a differentiated iron-based phosphate binder that is not polymer-based and free of aluminum, lanthanum and calcium for the treatment for hyperphosphatemia in CKD patients. -- A strategic alliance was formed with Ascentage Pharma Group Corporation Ltd. to research, develop and commercialize best-in-class targeted cancer therapeutics focusing on programmed cell death, or apoptosis. The alliance represents 3SBio's key strategic initiative to develop a novel pipeline in cancer therapeutics. -- Construction of the new EPIAO and TPIAO manufacturing plant in Shenyang was completed and work is underway on the application to the SFDA for Good Manufacturing Practice (GMP) certification. -- 3SBio submitted an application to the SFDA to conduct Phase I clinical trials for NuPIAO, the Company's second generation EPO product.

Dr. Jing Lou, chief executive officer of 3SBio, commented: "3SBio again delivered strong operating and financial performance in our third consecutive year since going public in early 2007. We are very pleased with our new strategic partnerships which we believe will provide an innovative platform for the future development of our product pipeline. We will also continue to invest in our internal R&D programs, including NuPIAO, our second generation EPO product. With construction of our Shenyang plant completed, we will now focus on seeking China GMP certification and validation as the next stage of our strategy to satisfy the growing demand in China for high quality, cost-effective oncology and nephrology treatments. Given the strong demand outlook f
'/>"/>

SOURCE 3SBio Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26

Related biology technology :

1. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
2. 3SBio Inc. to Hold Annual General Meeting
3. 3SBio Inc. Schedules 2007 Third Quarter Earnings Release On Tuesday, November 13, 2007
4. 3SBio Inc. To Present at the 19th Annual Piper Jaffray Health Care Conference
5. 3SBio Inc. Announces Appointment of Kevin Sow Peng Teo as Chief Financial Officer
6. 3SBio Inc. to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
7. 3SBio Inc. Schedules 2007 Fourth Quarter and Full Year Earnings Release on Wednesday, February 20, 2008
8. 3SBio Inc. Announces Change to the Board of Directors
9. 3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results
10. 3SBio Inc. Announces Promotion of David Chen as Chief Operating Officer
11. 3SBio Inc. Approves Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Report Details Biosimilar drugs – ... Do you want to find sales potentials of ... for those biological drugs from 2014, helping you ... data, R&D trends, opportunities and selling prospects. In ... 2024 at overall world market, therapeutic class, molecule ...
(Date:9/30/2014)... September 30, 2014 Proove Biosciences ... is excited to announce a new genetic test built ... Proove Pain Perception Test will provide physicians with ... why pain tolerance levels are stratified between individuals. With ... whether a person has a genetic predisposition that will ...
(Date:9/30/2014)... BUDAPEST, Hungary , September 30, 2014 /PRNewswire/ ... libraries and intuitive browsing of chemistry in documents ... providing chemistry software solutions and consulting services for ... extract chemical information and generate Markush structures from ... securing an organizations intellectual property, however generating and ...
(Date:9/30/2014)... and ROCKVILLE, Md., Sept. 30, 2014 ... focusing on commercializing market-relevant biohealth innovations and increasing access ... , announced today that venture capitalist, Tania Fernandez ... strategic advisor. Dr. Fernandez will be a member of ... which will provide up to $50 million in seed ...
Breaking Biology Technology:Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2
... , Feb. 3 ERT (Nasdaq: ERES ), announced ... full year 2009 on Thursday, February 25, 2010 , after the ... at 5:00 PM EST that day. , For the ... United States or 1-412-858-4600 when calling internationally. There will be a ...
... GENEVA , February 3 Viroblock ... anti-viral products, today,announced that Dr. Jamie Paterson will join ... Jamie Paterson , a British national, can look back at 20 ... was,Chief Commercial Officer at Neurim Pharmaceuticals. During his 18 years at,Procter ...
... Molecular Imaging Summit wrapped up today in Albuquerque, ... energy looking ahead. Nanotechnology is a quickly ... for applying technology in highly targeted ways. For ... target diseaseand treat many common and devastating diseases ...
Cached Biology Technology:ERT to Announce Fourth Quarter and Full Year 2009 Results on February 25, 2010 2Viroblock SA Hires Dr. Jamie Paterson as CEO and Closes Financing Round 2SNM's nanomedicine summit advances molecular imaging 2SNM's nanomedicine summit advances molecular imaging 3
(Date:10/1/2014)... take a healthy salad up a level by growing ... in leafy greens. , "In the long run, one ... the salad or making a pill from the plant ... at Case Western Reserve School of Medicine and leader ... cancer organization is funding the research with a three-year, ...
(Date:9/30/2014)... Mediterranean each year, but its deep-blue waters host ... 1,000 alien species, including fish, crustaceans, and algae ... activities. In the open-access journal Frontiers in ... analyzed data from a new information system developed ... introduction of alien species has changed the native ...
(Date:9/30/2014)... most comprehensive assessment conducted by the Ocean Health ... of 100 in overall health. In addition, for ... and the 15 ocean regions beyond national jurisdiction ... a healthy climate, safeguarding biodiversity and providing sustainable ... of the index, a partnership led by scientists ...
Breaking Biology News(10 mins):Scientists wield plant viruses against deadly human disease 2Scientists wield plant viruses against deadly human disease 3Biodiversity in the Mediterranean is threatened by alien species 2Rating the planet's oceans 2Rating the planet's oceans 3
... release is available in Spanish . , Barcelona, ... been discovered that neutrophils exist in the spleen without there ... group on the Biology of B Cells of IMIM (Hospital ... Sinai in New York, has also made it possible to ...
... imaging technologies and their contrast agents chemicals used during ... exposure to radiation or heavy metals, which present potential health ... applied. In an effort to mitigate these drawbacks, new research ... an iron-based contrast agent so that it only interacts with ...
... Calif., December 23, 2011 John C. Reed, M.D., Ph.D., ... Institute (Sanford-Burnham), have been named as Fellows of the American ... AAAS Fellow is an honor bestowed upon AAAS members by ... announced today in the AAAS News & Notes section of ...
Cached Biology News:Discovered the existence of neutrophils in the spleen 2Penn engineers develop more effective MRI contrast agent for cancer detection 2Penn engineers develop more effective MRI contrast agent for cancer detection 3AAAS and Sanford-Burnham announce 2011 fellows 2
... electrophoresis into an automated, high-throughput operation with ... system is ideal for analyzing multiple PCR ... Fully automated, robot-compatible, and ready to put ... your high-throughput screening assignments as easy as ...
...
Fluorescence Preserving Media, 100 mL...
Size & Applications: 20 ml Storage Temp.: -20C Shelf Life: 12 months ...
Biology Products: